Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis by Abrahamsson, SV et al.
PAGE	  1	  
 
Original Article 
Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and 
depletes IL-17 producing, mucosal associated invariant T cells in multiple sclerosis 
 
Sofia V. Abrahamsson1, Daniela F. Angelini2, Amy N. Dubinsky3, Esther Morel1,  
Unsong Oh4, Joanne Jones5, Daniele Carassiti1, Richard Reynolds1, Marco Salvetti6, Peter A Calabresi7,  
Alasdair Coles5, Luca Battistini2, Roland Martin8, Richard K. Burt9, and Paolo A. Muraro1* 
 
From the 1Division of Brain Sciences, Imperial College, London, UK; 2Neuroimmunology Unit, Fondazione 
Santa Lucia, Rome, Italy; 3Department of Pediatrics, University of California San Diego, La Jolla, CA, USA; 4 
Virginia Commonwealth University School of Medicine, Richmond, VA, USA; 5Department of Neurology, 
University of Cambridge, Cambridge, UK;  6Centre for Experimental Neurological Therapies (CENTERS), 
Sapienza University of Rome, Italy; 7MS clinic and research center, Department of Neurology, Johns Hopkins  
University, Baltimore, MD, USA;  8Neuroimmunology and MS Research, Department of Neurology, University 
Hospital Zürich, Zürich, Switzerland; 7Division of Immunotherapy, Feinberg School of Medicine, Northwestern 
University, Chicago, IL, USA 
 
*Corresponding Author. Address: 
 
Wolfson Neuroscience Laboratory 
Building 560/Burlington Danes, 4th floor 
Imperial College London 
160 Du Cane Road 
London W12 0NN, United Kingdom 
Tel: +44 (0) 207 594 6670 
Fax: +44 (0) 207 594 6548 
E-mail: p.muraro@imperial.ac.uk	  
	  
Running head: AHSCT resets immune balance in MS 
Number of words in abstract: 400 
Number of words in main text: 7,005 
Number of figures: 6 
Number of tables: 1 
Number of references: 48 
Number of supplementary figures: 6 
Number of supplementary tables: 3 
  
PAGE	  2	  
 
ABSTRACT 
Multiple sclerosis is an inflammatory disease of the central nervous system. Autologous 
haematopoietic stem cell transplantation has been tried as one experimental strategy for the treatment 
of patients with aggressive multiple sclerosis refractory to other immunotherapies. The procedure is 
aimed at ablating and repopulating the immune repertoire by sequentially mobilizing and harvesting 
haematopoietic stem cells, administering an immunosuppressive conditioning regimen, and re-
infusing the autologous haematopoietic cell product.  “Non-myeloablative” conditioning regimens 
utilizing an attenuated cytotoxic chemotherapy to achieve lymphocytic ablation without marrow 
suppression have been proposed to improve safety and tolerability. A recent clinical trial with non-
myeloablative autologous haematopoietic stem cell transplantation reported clinical improvement and 
inflammatory stabilization in treated patients with highly active multiple sclerosis. Aim of the present 
study was to understand the changes in the reconstituted immune repertoire bearing potential 
relevance to its mode of action. 
Peripheral blood was obtained from 12 patients with multiple sclerosis participating in the 
aforementioned trial and longitudinally followed for two years. We examined the phenotype and 
function of peripheral blood lymphocytes by cell surface or intracellular staining and multi-colour 
fluorescence activated cell sorting alone or in combination with proliferation assays. 
During immune reconstitution post-transplantation we observed significant though transient 
increases  in the proportion of CD4+ FoxP3+ T cells and CD56high NK cell subsets, which are cell 
subsets associated with immunoregulatory function.  Proportions of CD8+CD57+ cytotoxic T cells 
were persistently increased after therapy and were able to suppress CD4+ T cell proliferation in vitro 
with variable potency. In contrast, a CD161high proinflammatory CD8+ T cell subset was virtually 
ablated at all time-points post-transplantation. The expression of T cell receptor Vα7.2 and IL-18Rα 
revealed that the CD161highCD8+ T cells were mucosal-associated invariant T cells, a novel cell 
population originating in the gut mucosa but expressing the central nervous system-homing receptor 
CCR6. Detection of central nervous system-infiltrating mucosal-associated invariant T cells in post-
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mortem multiple sclerosis brain white matter active lesions confirmed their involvement in the disease 
pathology. Characterization of this T cell subset by intracellular cytokine staining demonstrated IFN-γ 
and IL-17 production and lack of IL-10 production, demonstrating a pro-inflammatory cytokine 
profile. Mucosal-associated invariant T cell frequency did not change after interferon-β treatment; and 
was more profoundly depleted after autologous haematopoietic stem cell transplantation than in 
patients who had received high-dose cyclophosphamide or alemtuzumab treatment alone, suggesting 
an additive or synergistic effect of the conditioning regime components. 
We propose that a favourably modified balance of regulatory and pro-inflammatory 
lymphocytes underlies the suppression of central nervous system inflammation in patients with 
multiple sclerosis following non-myeloablative autologous haematopoietic stem cell transplantation 
with a conditioning regimen consisting of cyclophosphamide and alemtuzumab. 
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INTRODUCTION 
Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous 
system (CNS) (Compston and Coles 2008). Current immune-modifying treatments are incompletely 
effective in patients with aggressive MS phenotypes. Autologous bone marrow- or haematopoietic 
stem cell transplantation (AHSCT) has been experimented in patients with aggressive forms of MS, 
aimed at suppressing CNS inflammatory activity and preventing further clinical deterioration 
(Saccardi et al. 2012). The mechanistic rationale for AHSCT is to first purge the mature immune 
system through intensive immune suppression and to then promote with haematopoietic stem cell 
support the reconstitution of a new immune system, free from aberrant responses that had previously 
developed within the individual’s adaptive immune system.  
Recent studies support a role for de novo regeneration of naïve T cells from the thymus 
(Hakim et al. 2005; Muraro et al. 2005), for enhanced immune regulation after AHSCT (Alexander et 
al. 2009; de Kleer et al. 2006; Zhang et al. 2009). In addition, a very recently published study by 
Darlington showed abrogation of the Th17 response following high-intensity AHSCT (Darlington et 
al. 2012). However, the cellular and molecular mechanisms underlying improved clinical course post-
AHSCT treatment are poorly understood and further complexity is added by the use of different 
immunosuppressive conditioning regimens. Non-myeloablative conditioning regimens have been 
recently proposed in order to improve tolerability and safety of AHSCT and allow treatment at earlier 
stages of disease than in the initial clinical trials (Burt et al. 2010). Current evidence for the immune 
modulatory mechanisms occurring after AHSCT remains scarce and no study to our knowledge has 
examined in detail the effects of a non-myeloablative conditioning transplantation regimen on the 
immune system. One recently published clinical trial of AHSCT utilizing a non-myeloablative 
conditioning regimen in highly active MS patients, has demonstrated sustained clinical stabilization in 
all and even improvement of disability in some patients (Burt et al. 2009). To investigate the 
immunological mechanisms underlying the remission of CNS inflammation, we performed 
longitudinal analysis of immune reconstitution in a group of patients treated in that trial. 
Our results show that following this non-myeloablative treatment protocol utilizing 
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cyclophosphamide and alemtuzumab for immunosuppressive conditioning, there were significant 
transient increases of CD4+CD25highFoxP3+ T cells and of CD56high NK cells, both phenotypes 
associated with immune regulatory function. We also observed robust and long-term increase of 
CD8+CD57+ T cells post-AHSCT. CD8+CD57+ T cells were in some patients able to suppress CD4+ T 
cell proliferation in ex vivo cell co-cultureswith superior efficiency. In contrast, we identified a 
population of CD161highCD8+T cells that were readily detectable in the blood of all patients pre-
transplant, but were maximally and permanently ablated during the whole 2-year post-AHSCT 
follow-up. Further characterization of the CD161highCD8+ T cell population found in MS patients’ 
blood pre-AHSCT revealed that these cells are mucosal-associated invariant T (MAIT) cells, a T cell 
subset associated with the gut (Dusseaux et al. 2011; Le Bourhis et al. 2010). High CD161-expression 
defined a subset of pro-inflammatory T cells that includes the majority of IL-17 producing CD8+ T 
cells and also produces IFN-γ and TNF-α but not IL-10. We confirmed that MAIT cells are able to 
migrate to the brain as they were present in the white matter and perivascular infiltrate of post-mortem 
MS brain tissue. Comparison of MAIT frequency in patients that received other MS treatments, 
including  the individual components of the conditioning regimen, high-dose cyclophosphamide and 
alemtuzumab monotherapy, revealed that autologous haematopoietic transplantation induced the most 
consistent depletion for up to two years post-therapy. 
The data demonstrate that the adaptive immune system reconstituted in patients with MS 
following the non-myeloablative AHSCT regimen is characterized by a favourably modified balance 
of pro- and anti-inflammatory lymphocyte subsets in the circulation, characterized by the expansion 
of immunoregulatory cells and radical depletion of a gut-associated CD161highCD8+ MAIT cell 
population, which produces IFN-γ and IL-17, bears a pro-inflammatory profile and is able to infiltrate 
the central nervous system. 
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SUBJECTS, MATERIALS AND METHODS 
Subjects, treatment and biological samples 
Patients with aggressive MS who failed to respond to licensed immune-modifying treatments were 
recruited for an IRB-approved clinical trial of non-myeloablative immunosuppressive conditioning 
with cyclophosphamide and alemtuzumab and AHSCT at Northwestern University, Chicago, IL (Burt 
et al. 2009). Following informed consent, peripheral blood for the research study was donated by 
subjects with MS undergoing AHSCT in the trial (n = 12).  The demographic and clinical 
characteristics of the non-myeloablative AHSCT trial patients who participated in this study are 
provided in Table 1. All these patients underwent non-myeloablative conditioning with 
cyclophosphamide 120 mg/kg and alemtuzumab 20 mg. Peripheral blood samples were obtained from 
the AHSCT patients at baseline within one month before haematopoietic stem cell (HSC) 
mobilization, and at 6 months, 1 and 2 years post-HSC reinfusion.  
PBMC samples for comparative immunological analysis were obtained from non-AHSCT 
MS patients (n = 40), and healthy individuals (n = 7). Of the non-AHSCT MS patients, 5 were 
untreated and 7 received standard disease-modifying treatment with interferon-beta (IFN-β): 
Betaferon® (n = 5), Betaseron® (n = 1), or Avonex® (n = 1). The 5 patients receiving Betaferon® 
were studied longitudinally before and during the first 9 months of treatment. One additional group 
included patients who had participated in a study of high-dose cyclophosphamide (HiCy, n = 7). 
Patients in this study received 50 mg/kg/d of cyclophosphamide intravenously for 4 consecutive days, 
followed by 5 µg/kg/day of granulocyte colony–stimulating factor 6 days after completion of HiCy 
treatment, until the absolute neutrophil count exceeded 1.0 × 109 cells/L for 2 consecutive days. The 
protocol has been described in detail elsewhere (Krishnan et al. 2008). Of the 7 patients, 5 had 
pretreatment baseline and post-treatment samples over a two year follow-up, one was available only at 
pretreatment baseline, and one only at 2 years post-therapy. The high-dose cyclophosphamide treated 
patients’ clinical characteristics are given in Supplementary table 1. The last group of patients 
received alemtuzumab monotherapy (n = 21) by participating in one of four studies: CAMMS-224 (an 
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investigator-led study - REC 03/078); CAMMS-223 (a Phase 2 randomised controlled trial) or CARE-
MS1 or CARE-MS2 (Phase 3 randomised controlled trials). Alemtuzumab was given for 5 days at 
baseline then for 3 days at month 12 (12 or 24mg/day); further cycles were given if there was clinical 
or radiological evidence of disease activity.  All patients consented to long-term follow-up and 
venipuncture for research purposes (CAMSAFE REC-11/33/0007). Only post-treatment samples were 
available for analysis. Demographic and clinical information on alemtuzumab treated patients is 
provided in Supplementary table 2.  
Peripheral blood mononuclear cells (PBMCs) were freshly separated by density gradient 
centrifugation and cryopreserved according to rigorously standardized protocols for subsequent use in 
batched, parallel immune analysis. All laboratory studies received ethical approval from Imperial 
College Research Ethics Committee (Ref. ICREC62D). 
 
Flow cytometry 
PBMCs were thawed in Dulbecco’s PBS and washed in FACS staining buffer (D-PBS, 1% FBS and 
0.01% sodium azide). Surface staining was performed on ice for 20 minutes and the cells were then 
analyzed on a 2-laser, 4 colour FACSCalibur flow cytometer, or for multicolour analysis on a 5-laser, 
18 colour LSRFortessa (Becton Dickinson, Franklin Lakes, NJ). Data were analysed using CellQuest 
(Becton Dickinson) and FlowJo software (TreeStar, Ashland, OR). 
Immune reconstitution and phenotyping studies: Multiplexed dilutions of monoclonal 
antibodies (mAbs) were used to characterize lymphocyte populations. The following antibodies from 
BD Biosciences (Oxford, UK) were used:  CD3-Cy-Chrome, CD3-RPE-Cy5, CD4-RPE-Cy5, CD4-
APC, CD5-APC, CD8-FITC, CD8-RPE-Cy5, CD8-PerCP, CD8-APC, CD11a-PE, CD14-APC, 
CD19-FITC, CD20-PE, CD25-FITC, CD25-PE, CD27-FITC, CD28-PE, CD31-PE,  CD45RA-FITC, 
CD45RA-PE, CD45RO-PE, CD45RO-APC, CD54-PE (ICAM-1), CD56-PE, CD57-FITC, CD58-
FITC (LFA-3), CD62L-PE, CD69-FITC, CD95-PE, CD161-FITC (clone DX12), and TCRαβ-FITC. 
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Other mAbs included CD49d-FITC and ILT2-PE (clone HP-F1) from Beckman Coulter (High 
Wycombe, UK).  
Regulatory CD4+ cell quantification: Staining for CD3- PE-Cy7 (BD Biosciences), CD4-
BV711, CD8 BV785, CD25-BV421, CD45RA-BV510 (BioLegend), and CD127-FITC (eBioscience) 
was performed before fixation and permeabilization of the cells. Intranuclear staining was performed 
according to the manufacturer’s instructions using Foxp3 AlexaFluor647 (clone PCH101) and Ki-67 
PerCP-eFluor710 (eBioscience). Blue Live/Dead Stain (Life Technologies, Grand Island, NY) was 
added to the samples before Foxp3 staining to for live versus dead cells discrimination.  
Characterization of MAIT cells: Multicolour staining was performed with the following 
antibodies: TCRVα7.2-APC, TCRVα7.2-PE (clone 3C10), CD4-BV711, CD4-BV785, CD8-BV711, 
CD8-BV785, CD45RA-BV510, CD161-BV421 or CD161-BV605, CCR6 (CD196) PerCP-Cy5.5, 
from Biolegend,	  San Diego, CA), CD161-PE and CD161-APC (clone 191B8) from Miltenyi Biotec 
(Gladbach, Germany); CD3-PE, ILT2 (CD85j)-APC, ILT2-PE, CD150 PE, and CD218 (IL-18R) 
FITC, from eBioscience (San Diego, CA); CCR6-PE from R&D Systems (Abingdon, UK), CD3-
APC-H7, and CD57 PE-CF594, CCR7 (CD197) PE-Cy7 (BD Biosciences) and CD45RO-ECD 
(Beckman Coulter). Blue Live/Dead Stain (Life Technologies) was included for exclusion of dead 
cells 
Characterization of TCRV expression: TCRVα7.2-FITC and TCRVα7.2-PE (clone 3C10) 
were obtained from Biolegend. For TCRBV usage CD8+ T cells, PBMCs were stained with anti-CD8-
PerCP (clone SK3, BD Bioscience) and anti-CD161-APC (clone 191B8, Miltenyi Biotec), in 
combination with pairs of FITC and PE-conjugated Abs to the following TCRVβ chains and assessed 
as previously described (Muraro et al. 2000): BV1–PE (clone BL37.2),  BV2–PE (clone MPB2D5), 
BV3–FITC (clone CH92), BV5S1–FITC (clone Immu157), BV5S2–FITC (clone 36213), BV5S3–PE 
(clone 3D11), BV6S7–FITC (clone OT145), BV7–PE (clone ZOE), BV8–FITC (clone 56C5.2), 
BV9–PE (clone FIN9), BV11–FITC (clone C21), BV12–FITC (clone VER2.32.1),  BV13S1–PE 
(clone Immu222), BV13S2-PE (clone H132), BV14–PE (clone CAS1.13),  BV16–FITC (clone 
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TAMAYA1.2), BV17–FITC (clone E17.5F3), BV18–PE (clone BA62.6), BV20–PE (clone ELL1.4), 
BV21S3–FITC (clone IG125), BV22–FITC (clone Immu546) and BV23–PE (clone AF23). 
TCRBV6S7 was obtained from Endogen (Thermo Fisher Scientific, Rockford, IL), TCRBV13S2 
from Santa Cruz Biotechnology (Santa Cruz, CA), and all other TCRBV mAbs were purchased from 
Immunotech (Marseille, France). 
Intracellular staining for cytotoxic enzymes: Cytotoxic potential was assessed by intracellular 
staining after fixation and permeabilization of the cells. Antibodies to perforin (PE) and granzyme B 
(AlexaFluor647) were purchased from BD Biosciences. 
 
Cytokine Production Assay 
PBMCs were stimulated for 5 hours with phorbol-12-myristate-13-acetate (PMA, 50 ng/ml) and 
ionomycin (1µg/ml) in the presence of brefeldin A (10 µg/ml, all from Sigma-Aldrich, Dorset, UK), 
ex vivo after overnight recovery in cell incubator with RPMI-1640 with 10% FBS. The cells were 
harvested and stained for relevant surface markers before fixation in 1% paraformaldehyde and 
permeabilization in 0.2% saponin. Intracellular cytokine production was assessed by IFN-γ Horizon 
V450, TNF-α PE-Cy7, IL-10 PE (BD Biosciences) and IL-17A AlexaFluor647 (eBioscience).  
 
Suppression assays 
PBMCs were thawed and left to recover overnight in RPMI-1640 with 10% FBS and 20 U/ml of IL-2. 
The following day, CD8+CD57+ and CD8+CD57- cells were obtained from PBMC using a magnetic 
microbead kit from Miltenyi Biotec. The percentage of NK cells found in all cases was ≤5%. The 
CD8-depleted fraction was stained with CFSE (Life Technologies and used as ‘effector’ (E) cells, 
while CD8+CD57+ and CD8+CD57- cells were used as “regulatory” (R) cells. Co-cultures were 
conducted at different R:E ratios in the presence of soluble anti-CD3 Ab (OKT3, 0.5 µg/ml, 
eBioscience). On day 4, the cells were washed and stained. Propidium iodide (PI, 1 µg/ml) was used 
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for dead cell exclusion. The percentage of cell proliferation was quantified on live (PI-) CD4-gated 
cells. To normalize the data providing from different donors, the proliferation in the absence of CD8+ 
cells (0:1 ratio) was considered 100% and the normalized proliferation was defined as the percentage 
of normalized proliferation at test ratio = (% dividing cells at test ratio / % dividing cells at 0:1 ratio) 
* 100, and % suppression was defined as (100 - % proliferation).  
 
Immunostaining of MS brain tissue 
Brain tissue blocks were provided by the UK Multiple Sclerosis Tissue Bank at Imperial College, 
London, UK. Post-mortem tissues were collected with fully informed consent via a prospective donor 
scheme with ethical approval by the National Research Ethics Committee (08/MRE09/31). Tissue 
blocks were screened and chronic active white matter lesions were identified as described previously 
(Magliozzi et al. 2007). Snap frozen brain white matter tissue blocks containing active lesions were 
selected from a subset of 9 progressive MS cases with high levels of CNS inflammation that formed 
part of a larger, well described case series (Howell et al. 2011). Tissue blocks (4 per case) cut at 
10µm, fixed for 10 min in ice-cold methanol and stained using a double sequential 
immunofluorescence technique first using anti-CD161 antibody (clone: B199.2, AbD Serotec, 
Oxford, UK) followed by anti-Vα7.2 antibody (clone: 3C10, Biolegend). Sections were incubated 
overnight at 4°C with the first primary antibody. Binding of biotinylated secondary antibody was 
visualized with the avidin-biotin horseradish peroxidase complex (Vector Laboratories, Burligame, 
CA) followed by 30 min incubation with tyramine (Sigma) in PBS containing 0.03% H2O2 according 
to a modified version of a method described by Adams (Adams 1992). The negative control consisted 
in the same protocol without incubation with tyramine. After 1h incubation with AlexaFluor546-
Streptavidin (Invitrogen, Eugene, OR) sections were washed, blocked with normal serum and 
incubated overnight at 4°C with the second primary antibody that was then visualized with an 
AlexaFluor488 secondary antibody (Invitrogen). Sections were counterstained with 4’,6-diamidino-2-
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phenylindole (DAPI, Sigma) for the localization of the nuclei and coverslipped with aqueous 
mounting medium Vectashield (Vector Laboratories). 
 
Statistical analysis 
Statistical significance was calculated using unpaired t-test, or by signed rank test for paired data that 
was not normally distributed. For multiple group comparisons, statistical significance was evaluated 
by parametric repeated measures analysis of variance (RM-ANOVA) and Holm-Sidak’s post-hoc test, 
or if the normality test failed, by non-parametric ANOVA on ranks and Dunn’s post-hoc test. An 
overall P value < 0.05 was considered significant. Values are given as mean ± SD for parametric 
comparisons, or median and interquartile range (IQR) for non-parametric comparisons. Graphical 
presentations were created with GraphPad Prism 5 and the statistical analyses were performed using 
SigmaStat v3.1 software (Systat Software, Chicago, IL). 
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 RESULTS 
Moderate contribution of thymic reactivation to immune reconstitution 
We first evaluated basic lymphocyte reconstitution after non-myeloablative AHSCT. Total absolute 
lymphocyte counts measured in whole blood were decreased up to the first year after treatment. The 
proportion of CD4+ cells within the total T cell population remained reduced for the entire two-year 
follow-up whereas no significant differences were detected in the percentages of CD8+ T cells, hence 
CD4/CD8 ratios were persistently decreased (Supplementary figure 1, Supplementary table 3).  
Previous work from our group and others has shown that AHSCT following myeloablative 
conditioning promoted increased output of de novo generated naïve T cells (Hakim et al. 2005; 
Muraro et al. 2005). We now examined immune reconstitution after non-myeloablative AHSCT 
through quantification of functional differentiation stages of T cells, including naïve (Tnaïve), central-
memory (TCM), and effector-memory (TEM) cells (Figure 1 A, Supplementary table 3). Post-AHSCT 
the proportion of Tnaïve cells (CD45RO-CD27+) was unaltered in the CD4+ subset and decreased in the 
CD8+ subset (from mean 61 ± 14% at baseline to 33 ± 12% at 2 years, P = 0.001). Conversely, TEM 
(CD45RO+CD27-) cells constituted a larger proportion of the total CD8+ pool than at baseline (from 
mean 4.2 ± 3.0% to 26 ± 14% at 2 years post-therapy, P < 0.001). There was a trend to an increase of 
CD4+ TEM cells. These results suggested that T cell reconstitution during the first two years post-
transplantation was predominantly driven by peripheral mechanisms of expansion.  
To ensure that effective thymic output was not masked by peripherally expanded naïve cells 
that had survived the preconditioning regimen, we enumerated naïve CD4+ T cells expressing CD31, a 
marker of recent thymic origin (Kimmig et al. 2002). Such recent thymic emigrant naïve cells, RTEs, 
constituted a higher proportion of all CD4+ cells at 1 year after therapy (from mean 30 ± 12% to 45 ± 
18%, a 50% increase, P = 0.025, Figure 1 B). Also the proportion of naïve CD45RA+CD45RO- cells 
expressing CD31 was increased for up to the first year post AHSCT (from mean 73 ± 13% to 84 ± 
9%, P = 0.005). These results show that during the first 2 years after non-myeloablative AHSCT the 
reconstitution of the circulating T cell pool is dominated by the expansion in the periphery of 
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differentiated T cells acquiring effector cell phenotypes, with a moderate but significant contribution 
of recent thymic output. 
 
Immunoregulatory cell surge early post-therapy 
To investigate the evolution of immunoregulatory cell populations post-therapy, we utilized in our 
analysis a number of markers specifically defining regulatory lymphocytes. At 6 months post-AHSCT 
there was a significant increase in the frequency of CD25high CD127-Foxp3+ cells in the CD4+ T cell 
subset (from median 0.11 [IQR 0.03 - 0.20]% to median 1.5 [IQR 0.9-1.9]%, P = 0.002, Figure 2 A), 
as well as an expansion of CD56high NK cells (from median 0.5 [IQR 0.3 – 1.3]% to 3.7 [IQR 2.8 – 
5.1]%, P = 0.001, Figure 2 B). The frequency of both cell subsets subsequently had returned to near 
baseline levels at 1 year after treatment. The changes in the absolute counts were not significant 
(Supplementary table 3). These data show that the proportions of regulatory T and NK cells are 
increased post-AHSCT. Their transient increase may help modulate activated effector cells during the 
early stages of antigen re-experiencing (O'Gorman et al. 2009). 
To assess whether the increased proportions of CD4+ Tregs were a result of increased 
homeostatic proliferation at 6 months, we assessed the expression of Ki-67, a cellular marker for 
proliferation. Whereas the percentage of Ki-67-expressing cells in the total CD4+ T cell population 
increased at 6 months (from 2.2 ± 1.1% to 5.6 ± 3.0%, P = 0.035; Supplementary figure 2 A), the 
percentage of actively proliferating Tregs, which was nearly 4 times that of the total CD4+ T cell 
population at pre-treatment baseline, did not change post-therapy (from 26 ± 12% to 20 ± 9%, P = 
NS; Supplementary figure 2 B). These results suggested that the increased relative frequency post-
transplantation of CD4+CD25highFoxP3+ Tregs was not due to a further increase in their proliferation 
rate. 
We were also interested in the potential contribution to treatment effect of CD8+CD57+ cells, 
a suggested immunoregulatory population (Autran et al. 1991; Mollet et al. 1998) that is significantly 
increased in the periphery of MS patients after treatment with myeloablative AHSCT (Muraro et al. 
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2005) and with glatiramer acetate (Ratts et al. 2006). CD57+ cells occupied a significantly greater 
proportion of the CD8+ T cell pool at all post-AHSCT time-points when compared to before HSC 
mobilization, reaching almost four times the baseline levels at 2 years post-transplantation (from 
mean 16 ± 9% to 59 ± 13% of all CD8+ T cells, P < 0.001; Supplementary figure 3 A). CD8+CD57+ 
T cells after treatment were mainly effector-memory cells (not shown) that produced high levels of 
IFN-γ, granzyme B (Supplementary figure 3 B-C) and perforin (not shown). Their phenotype was 
therefore consistent with that of classic cytotoxic CD8+ T cells (Chattopadhyay et al. 2009).  
To investigate the potential immunoregulatory ability of CD8+CD57+ T cells, we carried out 
suppression assays in which CD8-depleted PBMCs (‘effector cells’) were stained with CFSE and co-
cultured with increasing numbers of  CD8+CD57+ and CD8+CD57- (‘regulatory cells’) cells in the 
presence of a polyclonal (anti-CD3 Ab) stimulus. We then assessed  the inhibition of CD4+ T cell 
proliferation after 4 days in culture in the presence of both CD8+CD57+ and CD8+CD57- cells 
(Supplementary figure 3 D). The degree of inhibition by CD8+CD57+ cells varied in different subject 
and was either superior or equal to that of their CD57- counterpart at all ‘regulatory’ to ‘effector’ 
(R:E) ratios (Supplementary figure 3 E).These experiments demonstrated that cytotoxic CD8+CD57+ 
T cells are massively increased in number after AHSCT and, although CD57 was not a marker for 
inhibition per se, the subset comprised in some patients cells with strong suppressive activity. 
 
CD161highCD8+ are radically depleted after autologous haematopoietic transplantation and are 
invariant T cells associated with the gut mucosa  
Extensive multi-colour FACS phenotypic characterization of pre-treatment CD3+CD8+ cells (data not 
shown) revealed a distinct CD161highCD8αhigh/dim population (Figure 3 A). CD161highCD8+ T cell 
populations were present in the blood of all the patients before treatment (mean 7.8 ± 3.2% of total 
CD8+CD3+ cells). Of note, this population was radically depleted after AHSCT, and remained nearly 
undetectable for the whole follow-up period of 2 years (P < 0.001; Figure 3 B).  
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High expression of CD161 in CD8high/dim T cells defines the mucosal-associated invariant T 
(MAIT) cell subset (Dusseaux et al. 2011), a CD4- T cell subset defined by the expression of innate 
immune receptors and usage of the semi-invariant TCR Vα7.2-Jα33 (Treiner et al. 2003), with a 
preferential Vβ2 and Vβ13 gene expression (Tilloy et al. 1999; Treiner et al. 2005). We confirmed 
that more than 90% of the CD161highCD8+ T cell population in MS patients expressed TCR Vα7.2 and 
that high expression of CD161 was associated with expression of IL-18Rα, CCR6 and the SLAM 
molecule CD150 (Figure 3 C), consistent with a recent defining description of MAIT cells (Dusseaux 
et al. 2011). In contrast, a high expression of CD161 in the less frequent CD4-CD8- T cell subset did 
not define MAIT cells per se, as a large proportion of these CD4-CD8-CD161high cells did not express 
Vα7.2 (Supplementary figure 4 A). The CD161highCD8+ subset was also enriched in cells expressing 
TCR Vβ2 (mean 15.4 ± 6.4% of CD161highCD8+) and Vβ13.2 (mean 7.3 ± 3.3%), consistent with 
MAIT cells, and readily appreciated when expressed as the difference of TCR expression in the 
CD161highCD8+ T cells compared to all CD8+ T cells (Figure 3 D). The CD161highCD8+ T cell 
population showed a pattern of markers typical of antigen primed (CD45RA-CD45RO+CD27+/-
CD28+CD62L-) effector-memory cells (Supplementary figure 4 B). 
 
CD161highCD8+ MAIT cells are proinflammatory 
To assess the cytokine profile of CD161high, CD161dim, and CD161- CD8+ T cells, we carried out 
intracellular cytokine staining. CD161highCD8+ T cells from MS patients before AHSCT produced the 
pro-inflammatory cytokines IFN-γ, TNF-α, and IL-17 (Figure 4 A), but not the immuno-regulatory 
IL-10 (results not shown). Of all CD8+ subsets, the CD161highCD8+ subset contained the highest 
frequency of IFN-γ (77 ± 4%, P < 0.001, Figure 4 B) and TNF-α producing cells (56 ± 12%, P < 
0.001, Figure 4 C). The frequencies of CD8+ T cells producing IL-17 tended to be higher in the 
CD161high (median 1.4 [IQR 0.6-2.1]%) and CD161dim (median 0.6 [IQR 0.3-1.6]%, P = 0.040, 
Figure 4 D), but the analysis was not powered to detect the differences between the groups. However, 
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the CD161highCD8+ subset had the highest frequencies of cells producing both IL-17+ and IFN-γ 
(mean 0.14 ± 0.11%, P = 0.002, Figure 4 E). 
 When comparing the frequencies of CD161high, CD161dim, and CD161- cells within the 
cytokine-producing CD8+ T cells, the majority of the cells producing the widely expressed IFN-γ and 
TNF-α were CD161-CD8+ cells (that constitute 80-90% of the CD8+ T cell pool). Despite their 
considerably smaller numbers, CD161high cells constituted the majority of the total IL-17+ (mean 49 ± 
28 %) and IL-17+IFN-γ+ double positive cells (mean 51 ± 26%, Figure 4 F).  
Together these data confirmed that the CD161highCD8+ T cells present in MS patients before 
treatment and ablated post-therapy were proinflammatory effector MAIT cells, which contained the 
majority of IL-17 producing and IL-17/IFN-γ co-producing CD8+ T cells. 
 
MAIT cells are present in MS lesions 
The almost exclusive expression of CCR6 on CD8+ MAIT cells suggested their ability to enter the 
central nervous system (Reboldi et al. 2009). We next investigated whether CD161-expressing MAIT 
cells were also present in MS lesions in post-mortem brain tissue from 9 cases with high levels of 
inflammatory CNS infiltration. Staining with antibodies against CD8 and CD161 revealed the 
presence of double positive CD161+CD8+ cells within the inflammatory infiltrates of chronic active 
WM lesions (Figure 5 A). Since distinction of the CD161high versus CD161+ cells is not possible in 
tissue, we also stained for TCRVα7.2, which together with CD161 defines the MAIT cell population. 
We confirmed by dual immunofluorescent staining that CD161 and TCRVα7.2 double positive MAIT 
cells were indeed present in WM lesions inflammatory infiltrates in all 9 MS cases (Figure 5 B-C). 
The presence of MAIT cells in active white matter lesions in the MS brain suggested their 
involvement in MS pathogenesis, based on their cytokine profile, possibly as proinflammatory 
effectors. 
 
PAGE	  17	  
 
Circulating MAIT cell numbers are differentially affected by diverse immunotherapies 
We next asked whether depletion of MAIT cells in the periphery was specific for the autologous 
haematopoietic transplantation protocol and to which extent other treatments for MS affected MAIT 
cell frequencies. We first confirmed the depletion of CD161highVα7.2+ CD8+ MAIT cells from the 
periphery of AHSCT patients (Figure 6 A). After AHSCT, the frequencies of CD8+ MAIT cells 
decreased (from a mean 12.1 ± 7.4% of CD8+ cells at baseline, to mean 0.6 ± 0.2% at post-therapy 
follow-up 2 years, P < 0.001, Figure 6 B). In contrast, the frequency of CD161highCD8+ cells, a good 
surrogate of CD8+ MAIT’s (Supplementary figure 4 A)  in the blood of patients treated with IFN-β 
was unchanged 6 months after treatment (Supplementary figure 5). 
We then set out to dissect the effects on MAIT cells in vivo from each of the two components 
of the immunosuppressing conditioning regime, cyclophosphamide and alemtuzumab, by studying 
PBMC samples from patients who had been treated with either high-dose cyclophosphamide (HiCy) 
or alemtuzumab alone. We measured the frequencies of CD8+ MAIT cells at pre-therapy baseline and 
at 2 years post-therapy in 5 patients who underwent immunosuppression with high-dose 
cyclophosphamide. An additional 2 patients had only pre or post-therapy samples available. The 
CD8+ MAIT cells were profoundly reduced in 4 out of 6 patients, but persisted at high levels post-
therapy in two subjects (Figure 6 C). We also measured MAIT frequency in patients who received 
treatment with alemtuzumab monotherapy (n = 21). Patient samples were taken at different time 
points after the last alemtuzumab infusion (range 2-38 months), however the time seemed not to affect 
the CD8+ MAIT cell frequencies within the sampled period as they did not correlate with the time 
after treatment (Figure 6 D). 
When comparing AHSCT, HiCy and alemtuzumab monotherapy post-treatment samples 
(Table 1) , MAIT cell frequencies in both the CD8+ (Figure 6E) and the CD4-CD8+ (Figure 6 F) cell 
subsets, as well as in the total CD3+ population (Figure 6 G) were low in all three groups, being 
lowest in the AHSCT-treated patients. MAIT cells in all subsets (CD8+, CD4-, and CD3+) were 
significantly higher in the HiCy samples as compared to both the AHSCT and alemtuzumab 
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(monotherapy) treated patients (CD8+ MAIT cells: P = 0.013; CD4- MAIT cells: P = 0.006; CD3+ 
MAIT cells: P = 0.002). These results were driven by MAIT cell numbers remaining high in 2 out of 
the 6 high-dose cyclophosphamide patients. Whereas the mean frequencies were not statistically 
different between AHSCT and alemtuzumab treated patients (CD8+ MAIT cells: P = 0.08; CD4- 
MAIT cells: P = 0.08: CD3+ MAIT cells: P = 0.09), the variance between the two patient groups was 
different (CD8+ MAIT cells: F < 0.001: CD4- MAIT cells: F =0.004: MAIT / total CD3+: F = 0.011) 
indicating that the frequencies of all MAIT cell populations were differently distributed in the two 
treatment groups, with a greater variability of MAIT cell numbers in the alemtuzumab monotherapy 
treated group.  
Our study was not designed to ascertain if a correlation might exist between the degree of 
ablation of circulating MAIT cells and the persistence or recurrence of MS disease activity after the 
treatments. We attempted, however, to detect a potential association by stratifying patients according 
to post-therapy circulating CD8+ MAIT cell frequency and examining their clinical course. The 
patients who underwent AHSCT had predominantly low frequencies (<1%) of circulating 
CD8+MAIT cells post-therapy. There were only two post-therapy samples that had CD8+ MAIT 
frequency >1% in the AHSCT cohort (n = 12) and they were the 12-month sample from patient CC09 
who relapsed at 16 months and the 6-month sample from patient CC12 who relapsed at 6 months 
(CD8 MAIT frequencies 1.1% in both). The remaining two patients who had a relapse after AHSCT 
(both at 12 months), however, had low (<1%) MAIT frequencies at all the post-transplantation time 
points assessed. In the high-dose cyclophosphamide treated cohort (n = 7) there were two patients 
(HiCy1 and HiCy2) who had high MAIT cell frequency post-therapy (10.4% and 15.7%, 
respectively).  Interestingly, they were also the two patients with highest MAIT frequency at the pre-
treatment baseline (13.8% and 17.0%, respectively), and the highest disability both pre-treatment 
(EDSS 7) and post-treatment (EDSS 6.5 and EDSS 7, respectively) in the cohort (Supplementary 
Table 1). Of these two patients, one (HiCy1) had had a stable post-treatment course; the other (Patient 
HiCy2) had a high inflammatory activity in the CNS, with 20 gadolinium-enhancing lesions at month 
27 post-therapy. In the larger cohort  of alemtuzumab-only treated patients (n=19 after excluding two 
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patients who were being treated with IFN-B at the alemtuzumab baseline, in order to avoid potential 
confounding effects on the clinical measures), where a fair range of MAIT cell levels and range of 
disease activity following therapy were documented, we were able to stratify patients in 3 groups 
according to CD8+ MAIT cell frequency: low (<1%), intermediate (between 1% and 90th percentile 
value in the cohort) and high (90th percentile and higher; Supplementary Fig. 6A); and examined the 
clinical data in the three groups (Supplementary Fig. 6B-D). Of note, the two patients with high 
frequency of CD8 MAIT cells after alemtuzumab treatment (Patients Alem10 and Alem20) had 
highly active MS before treatment (both had 3 relapses in the preceding 12 months), were at the high 
end of the range of disabilities at baseline within the cohort (EDSS 6 and 6.5, respectively) and 
relapsed post-treatment (1 and 4 relapses respectively; the latter being the highest number observed 
within the cohort). Their disability, however, markedly improved after alemtuzumab treatment 
(decreasing to EDSS 2 in both patients). In the low- and intermediate CD8 MAIT frequency group 
there were 4 patients who had no relapses post-treatment (2 and 2, respectively); one or more relapses 
post-therapy were documented  in  5/7 and 8/10 patients in these groups, respectively.
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DISCUSSION 
In this study we investigated the immune reconstitution in patients who underwent non-myeloablative 
conditioning AHSCT for treatment of their highly active, conventional treatment-resistant forms of 
MS. We observed immunological changes which were consistent with a favourably redistributed 
balance of regulatory vs. proinflammatory lymphocytes, resulting from the relative increase of cells 
with regulatory profile and the radical, virtually complete depletion of a CD8+ T cell subset 
expressing high levels of CD161 and producing IFN-γ, TNF-α, and IL-17. Based on their chemokine 
and cytokine receptor profile as well as its semi-invariant TCR rearrangement we characterized 
CD8+CD161high cells as MAIT cells and demonstrated their presence in brain white matter 
lymphomononuclear cell infiltrates in postmortem MS white matter tissue, supporting its potential 
pathogenic relevance. 
Different AHSCT conditioning regimens have been explored for treatment of aggressive 
forms of immune-mediated disorders. Non-myeloablative regimens have been proposed for two main 
reasons: (1) the treatment should primarily target the lymphoid, not the myeloid compartment; and (2) 
improved safety and tolerability facilitate treating patients during the appropriate window of 
therapeutic opportunity at earlier stages of disease (Burt et al. 2008). A recent clinical trial showed 
that non-myeloablative AHSCT can arrest or reverse neurological deterioration in patients with highly 
active, treatment-resistant relapsing-remitting MS with acceptable safety (Burt et al. 2009). Here we 
investigated key aspects of immune reconstitution in 12 patients, who had all received the same 
(cyclophosphamide/alemtuzumab) non-myeloablative conditioning regimen in that trial.  
Analysis of the naïve and memory T cell repertoire after non-myeloablative conditioning 
AHSCT revealed a markedly different quality of immune reconstitution when compared with our 
previous study of a myeloablative conditioning regimen utilizing cyclophosphamide and total body 
irradiation (CY/TBI) (Muraro et al. 2005). While naïve T cells following CY/TBI had a biphasic 
reconstitution, with initial depletion followed by recovery and increase to twice their baseline 
frequency (Muraro et al. 2005), in the present study the frequencies of naïve CD4+ T cells and of 
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naïve CD8+ T cells were, respectively, unchanged and reduced throughout the post-therapy follow-up. 
We detected, however, a moderate but statistically significant degree of CD4+ recent thymic emigrant 
expansion during the first year of follow-up, demonstrating a degree of reactivation of the thymus. 
Together, these results suggest that the non-myeloablative conditioning regimen that we investigated 
in our study induced a less extensive replacement of the mature T cell repertoire than the previously 
reported myeloablative regimen.  
We have used CD31 as an established marker to enumerate T cells recently differentiated 
from haematopoietic stem cells (HSCs), however these methods cannot distinguish whether the HSCs 
were survivors from the bone marrow or from the infused autologous graft. Since a non-myeloablative 
conditioning protocol by definition causes minimal bone marrow suppression, it is likely that HSCs 
from both the patient’s bone marrow and the graft contribute to immune reconstitution. 
These results prompted us to hypothesize that the therapeutic effect of AHSCT on CNS 
inflammation in MS may not require a complete renewal of the T cell repertoire but could be 
mediated by the normalization of a balance between pro-inflammatory and immunoregulatory cells. 
Several studies have described defects in the number or function of CD4+ regulatory cells in MS 
(Venken et al. 2008; Viglietta et al. 2004). Our longitudinal analysis of regulatory T-cell frequency 
showed a significant surge in CD4+CD25+CD127-Foxp3+ cells proportion relatively early (6 months) 
post-transplantation. These results are consistent with previous work in juvenile idiopathic arthritis 
and in systemic lupus erythematosus, suggesting that recovery of CD4+CD25high T cells might play a 
role in the mode of action of AHSCT (Alexander et al. 2009; de Kleer et al. 2006). Expansion of 
CD4+ Tregs has also been shown after alemtuzumab monotherapy (Cox et al. 2005) leaving open the 
possibility that increased Treg numbers are part of a common response following intensive 
lymphodepletion.  
We considered the possibility that the transiently increased numbers of Tregs after AHSCT 
were the result of a boosted homeostatic proliferation at 6 months. Tregs had a higher proliferation 
than the whole CD4+ population at baseline and there was no change at 6 months post-therapy, despite 
that the total CD4+ patient population was proliferating much more actively than at baseline. These 
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results suggest that increased active proliferation did not account for the higher numbers of regulatory 
T cells post-transplantation; rather, it appears that Tregs either are more resistant to the 
immunosuppressive regime or they recommence to be exported from the thymus and steadily 
proliferate in the periphery, with a gain of their relative proportion in the lymphopenic CD4+ 
compartment, which is likely to give them a regulatory advantage over re-emerging effector T cells. 
We also describe a transient increase of CD56high NK cells, a NK cell subset with 
immunoregulatory potential (Jiang et al. 2011). CD56high NK cells have been reported to expand and 
mediate therapeutic effects in MS patients receiving daclizumab (Bielekova et al. 2006) and IFN-β 
(Vandenbark et al. 2009). We speculate that the early expansion of CD4+ Tregs and regulatory 
CD56high NK cells may be important for the control of the immune system during the early antigen 
priming of re-emerging lymphocytes, as previously suggested (O'Gorman et al. 2009). 
Next, we focused our analyses on the functional significance of different types of phenotypic 
CD8+ T cell effector-memory cell subpopulations, which demonstrated significant changes in their 
frequencies in pre- to post-AHSCT blood samples. We have previously reported a prominent increase 
of CD57+CD28-CD8+ T cells, a subset of CD8+ T cells with proposed suppressor function (Mollet et 
al. 1998), after myeloablative AHSCT (Muraro et al. 2005). We have reproduced and extended this 
observation in the present study. CD8+CD57+ T cells were significantly and persistently increased 
throughout the post-transplantation follow-up. Functional characterization of CD57- and CD57+ CD8 
T cells through co-culture suppression assays showed that although both populations contained cells 
with suppressive activity, the suppressive effect of CD57+CD8+ cells was variable and either much 
greater or equal to their CD57- counterpart. These observations suggested that CD57 may not be per 
se a marker defining immunoregulatory CD8+ T cells, as previously suggested. Interestingly, ILT2, a 
marker associated with regulatory function is expressed by a majority of CD57+CD8+ cells and is 
differentially regulated during the post-AHSCT follow-up (data not shown). Further work is required 
to define the key determinants of CD8+CD57+ regulatory activity. 
Our detailed characterization of CD8+ T cell reconstitution included several NK markers 
known to be expressed on T, NKT and NK-like T cells (data not shown) and revealed that a 
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CD161highCD8+ T subset, readily detectable in all patients before treatment, was radically depleted 
after AHSCT. We also demonstrate that more than 90% of the CD161highCD8+ cell population in MS 
patients express TCRVα7.2 and IL-18Rα, and therefore represent mucosal-associated invariant T 
(MAIT) cells, a subset recently described for their antimicrobial activity (Kjer-Nielsen et al. 2012; Le 
Bourhis et al. 2010). MAIT cells have been described as noncycling, tissue-targeted cells that secrete 
IL-17 and express high levels of the multiple drug transporter protein ABCB1, which confers them 
resistance to ABCB1-effluxed chemotherapy (Dusseaux et al. 2011).  We confirmed that high 
expression of CD161 defines a proinflammatory CD8+ memory MAIT population that produces IFN-γ 
and contains the IL-17 producing CD8+ T cells in MS patients, in agreement with recent studies 
describing CD161high cells as a chemotherapy-resistant and tissue-homing proinflammatory CD8+ 
subpopulation (Billerbeck et al. 2010; Turtle et al. 2009). These MAIT cells likely possess some 
plasticity depending on the inflammatory environment – It was recently shown that their IL-17 
production was enhanced by costimulation with IL-1β, while presence of IL-12 induced a Tc1-like 
function (Turtle et al. 2011). Our description of a post-treatment depletion of CD8+ T cells that 
produce IL-17 (Tc17) is novel and complementary to recent data from a study of AHSCT employing 
a high-intensity immunosuppressive protocol. The study by Darlington et al shows that the capacity to 
mount Th17 responses is diminished post-therapy, although the Th1 responses remain unaltered 
(Darlington et al. 2012). Together, their study and ours suggest that alterations of the Th17/Tc17 
pathways are crucial mechanisms of immune reconstitution post-AHSCT. 
The demonstration that MAIT cells are pro-inflammatory contrasts with the interpretation of 
Miyazaki et al., who despite describing MAIT cells as a population that secrete high levels of 
proinflammatory cytokines IL-17 and  IFN-γ, interpret them as immunoregulatory cells able to 
suppress Th1 responses in MS (Miyazaki et al. 2011). We believe that without intracellular cytokine 
staining assays it is difficult to ascertain whether MAIT cells truly inhibit IFN-γ production from T 
cells. The interpretation of results from their co-culture system is made problematic by the fact that 
‘MAIT-depletion’ in their co-culture assays was performed by depletion of CD161 expressing cells, 
and thus would have depleted not only CD161high MAIT cells, but also the widely present CD161dim 
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effector CD4 (IFN-γ and IL-17 producing cells, and even some regulatory populations), CD8 T cells, 
including CD57+CD8+ cells), and NK cells. After the depletion of several functionally important cell 
subsets, it is difficult to define the effect of any one specific cell population. In our study, by 
intracellular cytokine staining and selective gating on CD161high, -dim and negative cells we 
demonstrate production of IL-17, IFN-γ and TNF-α and no production of IL-10 by CD161high cells, 
consistent with a pro-inflammatory function and in agreement with a majority of other studies 
(Annibali et al. 2011; Billerbeck et al. 2010; Dusseaux et al. 2011; Walker et al. 2012). 
The involvement of IL-17 producing CD161highCD8+ T cells in MS pathology is plausible 
when considering that the majority (> 70%) of CD8 T cells in acute and chronic active MS lesions 
were reported to express IL-17 (Tzartos et al. 2008). The potential relevance of CD161highCD8+ cells 
in MS was recently underpinned by the study by Annibali et al. (Annibali et al. 2011) that showed 
that the expression of KLRB1, the gene coding for CD161 and one of the non-MHC risk alleles with 
the highest statistical association to MS (Hafler et al. 2007), was increased in affected monozygotic 
twins as compared to their healthy co-twins. In that study, the frequency of CD161+ cells in the CD8+ 
T cell subset was significantly increased in the blood of MS patients when compared to healthy 
controls. Furthermore, CD161+CD8+ T cells were detected amongst tissue-infiltrating cells in post-
mortem MS brain tissue (Annibali et al. 2011).  
Furthermore, by examining immune cell infiltrates in postmortem MS brain white matter 
tissue from cases with high levels of inflammation we confirm that MAIT cells are present in white 
matter lesions, confirming their ability to migrate into the central nervous system as suggested by 
their tissue-homing receptor profile. In a separate study extensively characterizing CD161+ 
lymphocytes in MS tissue the presence of MAIT cells was quantified in the white matter as well as in 
the meningeal inflammatory infiltrates, where they represented 17% and 8% of total CD161+ cells, 
respectively (Carassiti et al., manuscript in preparation). These data extend the previous 
demonstration of the TCRVα7.2Jα33-transcript in the white matter lesions (Illes et al. 2004). 
Together with the proinflammatory profile, demonstrated in circulating cells, these observations 
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suggest that MAIT cells are probably implicated in the development of CNS immune-mediated injury 
in MS.  
CD161highCD8+ MAIT cells express CCR6, a receptor that is involved in transmigration of T 
cells into the central nervous system and in the initiation of EAE (Reboldi et al. 2009). CD161 itself 
also plays a role in trans-endothelial migration of T cells (Poggi et al. 1997). MAIT cells produce high 
levels of inflammatory cytokines IFN-γ and TNF-α,, and are the highest producers of IL-17; IL-17R is 
expressed on blood-brain barrier (BBB) epithelial cells in MS lesions and IL-17 increases the 
permeability of the BBB (Kebir et al. 2007). Furthermore, the commensal gut flora has been shown to 
enhance the IL-17 response and to be required for the development of myelin-specific autoimmunity 
in an experimental model of demyelination (Berer et al. 2011), which corroborates the implication of 
gut immunity in autoimmune disease. Taken together, these studies and our own data strongly suggest 
an important role for CD161highCD8+ MAIT cells in MS pathogenesis. 
It was, therefore, of great interest to consider to which extent the two principal components of 
the immunoablative chemo- / biological therapy conditioning regimen, high-dose cyclophosphamide 
and alemtuzumab contributed to the observed depletion of MAIT cells. We hence obtained PBMC 
from patients treated in a protocol using high-dose cyclophosphamide at Johns Hopkins University; 
and in a protocol of alemtuzumab at the University of Cambridge. There was no post-therapy 
depletion of MAIT cells in 2 out of 6 analyzed high-dose cyclophosphamide treated patients. PBMC 
obtained from patients treated with alemtuzumab at different time after their last infusion of the 
antibody had low frequency of MAIT cells although the significantly greater variance suggested that 
the frequency was higher in some alemtuzumab monotherapy-treated individual. This variance was 
independent of the time since the last treatment infusion. Our data suggest that both high-dose 
cyclophosphamide and alemtuzumab alone have the potential to deplete circulating MAIT cells but 
larger numbers of cells may escape depletion from either treatment alone than from autologous 
haematopoietic stem cell transplantation with a conditioning regimen that includes both 
cyclophosphamide and alemtuzumab. Based on our data we speculate that alemtuzumab may account 
for the majority of the MAIT-depleting effect, but that the combination of alemtuzumab with 
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cyclophosphamide in the transplantation conditioning regime (which was also preceded by a few 
weeks by the use of cyclophosphamide for haematopoietic cell mobilisation, which may contribute to 
the ablative effect) may have additive or synergistic effects, resulting in a more complete depletion.  
Differentiating responders and non-responders to a given treatment and measuring potentially 
relevant biological variables might allow gaining valuable insight into its mechanism of action. 
Dichotomising clinical responses to therapy, however, is not always straightforward. Clinical and 
MRI follow-up of the AHSCT patients showed complete disease remission post-therapy in 8/12 
patients. Four patients had a single relapse during the first 2 years post-transplantation (vs. 2 relapses 
each in the 12 months before transplantation) yet at the end of the ≥ 24 month follow-up post-AHSCT 
the EDSS scores of all relapsing patients were either improved (n = 3) or unchanged (n = 1) compared 
to pre-treatment baseline, suggesting that their MS course had been stabilized or at least attenuated. 
For the interpretation of our immunological studies, therefore, we felt more appropriate to regard the 
clinical outcomes in these 4 patients as partial/incomplete responses rather than treatment failure, and 
we show here the immunological results from all patients conjointly. We applied the same 
consideration to the other treatments. Indeed, stratification analysis showed no statistically significant 
differences between the complete and partial responders groups in any of the immune parameters 
being investigated (data not shown), including recovery of CD4+ T cell numbers and CD4/8 ratios 
that were recently described as surrogate marker of treatment response to alemtuzumab (ADD 
REFERENCE Cossburn et al Neurology 2012), although we cannot rule out that some differences 
might have been detected if larger numbers of patients had been available.  
Based on the pro-inflammatory profile of MAIT cells, their radical post-therapy depletion of MAIT 
cells observed after AHSCT and the more variable depletion observed after other treatments we 
hypothesized that their frequency might align most closely with therapeutic efficacy and interrogated 
the data to detect a potential relationship. Our study had not been designed to examine a correlation of 
MAIT cell numbers and clinical or imaging response to treatment and was statistically underpowered 
to detect such potential correlations. Only a descriptive analysis of a potential association therefore 
was performed. In the AHSCT cohort, it was of note that the samples with the highest frequency 
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(1.1%) of residual CD8+ MAIT cells were from two time points of two patients who subsequently 
had a relapse. Interestingly, CD4+ T cells in the sample associated with relapse at 6-month follow-up 
showed a greatly enhanced reactivity to myelin basic protein (Supplementary figure 7). In the high-
dose cyclophosphamide cohort, one of two patients with high (>10%) CD8+ MAIT cell frequency 
post-therapy had an inflammatory flare with high number of enhancing lesions; the other patient 
remained stable. In the alemtuzumab cohort, the two patients with high CD8+ MAIT cell frequency 
post-therapy (7.4% and 3.6%) both had relapses post-therapy (1 and 4 relapses, respectively). 
Interestingly, all four patients with high MAIT cell frequency post-therapy in the high-dose 
cyclophosphamide- and in the alemtuzumab cohorts had high disability levels pre-treatment, although 
disability improved (even if relapses occurred) in the two patients who received alemtuzumab, which 
has been suggested to exert neuroprotective effects in vivo based on the demonstration of induction of 
neurotrophic mediators in vitro (add Jones Brain 2010 reference). 
Although these observations are intriguing and support the implication that MAIT cells are 
active perpetrators of inflammatory disease activity in MS, it should be noted that in all 3 cohorts 
(AHSCT, high-dose cyclophosphamide and alemtuzumab), there were patients with low circulating 
MAIT cells who had relapses or MRI activity post-therapy; and there was one patient (HiCy1) who 
had high circulating MAIT cell frequency yet remained clinically stable. These observations suggest 
that there is no exclusive association of either low frequency of circulating MAIT cells with disease 
remission or association of high frequency of circulating MAIT cells with disease relapse.  The data, 
therefore, should be interpreted with caution. Future studies in larger numbers of patients, with 
prospective enumeration of MAIT cells and clinical monitoring before and during treatment are 
warranted to establish if a correlation of MAIT cell number and clinical course exists.  These studies 
could address the hypotheses generated from the present study that MAIT cells are implicated as 
detrimental inflammatory mediators of disease and may represent a biomarker of treatment response 
in MS. 
In conclusion, our data show significant qualitative and functional changes in the 
reconstituted immune response following the non-myeloablative AHSCT regimen.  Data on 
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differentiation factors describing a reciprocal relationship between Treg cells and Th17 cells (Bettelli 
et al. 2007; Mucida et al. 2007) suggest that the balance between regulatory and pro-inflammatory 
cells is reset by tightly controlled processes that coordinate functional differentiation of lymphocytes 
during immune reconstitution. Indeed, we demonstrate increased numbers of circulating cells with 
regulatory potential as well as the elimination of a pro-inflammatory IL-17-, TNF-α-, and IFN-γ- 
producing CD8+ cell population which corresponds to the recently described, gut-derived MAIT cell 
population. We further show that CD8+ MAIT cells, which express CCR6, actually infiltrate MS 
lesion tissue. Taken together, our results suggest that CD8+ MAIT cells might be involved in MS as 
inflammatory mediators and could represent a disease and a treatment biomarker as well as, 
potentially, a therapeutic target. 
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